KRAS and cancer: reported a novel MEKi-based regimen using a type II RAF inhibitor (RAFi) with an allosteric MEKi has tremendous improvement in suppressing the acquired MEKi resistance among cancers including KRAS, NRAS, NF1, BRAF non-V600, and BRAF V600 mutations through sequestering MEK from ERK.